American Heart Association (AHA) Scientific Sessions 2022

Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia

Roshini Claire Anthony, 20221223180001

Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.

HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization

Roshini Claire Anthony, 20221221180001

Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.

Rapid IV sotalol loading feasible, safe for AF patients

Audrey Abella, 20221218100000

IV sotalol administered rapidly as a loading dose to initiate oral sotalol therapy is feasible and safe for rhythm control in individuals with atrial fibrillation (AF), the DASH-AF study finds.

Do supplements measure up to statins for lipid-lowering?

Audrey Abella, 20221213100000

In individuals with increased 10-year risk for ASCVD*, rosuvastatin 5 mg significantly reduced LDL-C** and other lipid and inflammatory biomarkers compared with placebo and six widely used heart health supplements, results from the SPORT*** trial have shown.

Low-dose polypill: Another step forward in hypertension management?

Roshini Claire Anthony, 20221212150001

A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.

First-line ablation averts AF progression

Elaine Soliven, 20221207000000

Among patients with paroxysmal atrial fibrillation (AF), initial treatment with cryoballoon ablation reduced the incidence of persistent AF through 3 years of follow-up compared with antiarrhythmic drug (AAD) therapy, according to the PROGRESSIVE-AF* trial presented at AHA 2022.

Post-PCI bivalirudin infusion reduces death, bleeding vs heparin

Roshini Claire Anthony, 20221204100001

Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.

IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients

Audrey Abella, 20221202100000

In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.

Chinese herbal med cuts MACCE in STEMI, but questions remain

Elvira Manzano, 20221201000000

Tongxinluo, added to guideline-directed therapy, improves outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) in the large, multicentre CTS-AMI* study. But experts are clamouring for more evidence of efficacy.

Surgery outperforms endovascular therapy in CLTI

Elaine Soliven, 20221117100000

Surgical revascularization results in fewer major adverse limb events (MALE) or death compared with endovascular therapy in patients with chronic limb-threatening ischaemia (CLTI) who had an adequate single-segment great saphenous vein (SSGSV) in the BEST-CLI* trial. Outcomes were similar for both strategies in those who lacked an adequate SSGSV.